laboratory

Verifying your product safety is faster and easier than ever with AQF’s streamlined lab testing service
More

research

DSL BIOTECH is a biotechnology company that discovers and develops drugs to target validated disease pathways in a unique and transformative way.
More

technologies

Anticalin proteins promise to become safer drugs with improved efficacy profiles and more convenient routes of administration than existing targeted biologic drugs.
More

experience

Our clinical pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases
More

publications

Pretargeting approaches rely on the injection of bispecific antibodies capable of recognizing both an accessible disease marker and a small ligand, which is typically administered at a later stage and which serves as delivery vehicle for a payload for imaging or therapy applications. In the oncology field, pretargeting strategies have exhibited extremely promising biodistribution results and in vivo selectivity, but have often relied on the cumbersome preparation of multispecific antibodies by chemical conjugation techniques. Here, we describe the design, production, and characterization of a novel class of bispecific multivalent antibody products, which contain both antibody fragments and an anticalin moiety for the simultaneous recognition of tumor-associated antigens and a small organic molecule.